Opinion|Videos|October 7, 2024
Treatment Considerations for Patients With HER2+ NSCLC
Key Takeaways
- Clinicians must balance therapeutic benefits and risks, particularly concerning adverse events like interstitial lung disease, by tailoring treatment plans to individual patient needs.
- Evolving strategies to address resistance to HER2-directed therapies focus on understanding resistance mechanisms and developing novel agents or combination therapies.
Panelists discuss how clinicians carefully weigh the efficacy of HER2-directed therapies against their safety profiles, particularly focusing on managing serious adverse events like interstitial lung disease, while also considering emerging strategies to combat resistance to these treatments as research in the field progresses.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do clinicians balance the efficacy and safety profiles of these therapies, particularly considering adverse events like interstitial lung disease?
- (Bazhenova) How might strategies to address resistance to HER2-directed therapies evolve with ongoing research?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale
2
ACA Enrollment Erosion Deepens After Open Enrollment Ends
3
Efgartigimod Effective in Broad Subsets of Patients With gMG
4
Alopecia Areata Takes a Hidden Toll on Work, Relationships, and Self-Care
5